Production (Stage)
Structure Therapeutics Inc.
GPCR
$24.55
-$0.10-0.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.96% | 2.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.66% | 2.67% | |||
| Operating Income | -19.66% | -2.67% | |||
| Income Before Tax | -28.59% | -7.25% | |||
| Income Tax Expenses | -27.94% | 47.83% | |||
| Earnings from Continuing Operations | -28.38% | -7.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.38% | -7.36% | |||
| EBIT | -19.66% | -2.67% | |||
| EBITDA | -19.75% | -2.71% | |||
| EPS Basic | -28.28% | -7.19% | |||
| Normalized Basic EPS | -95.36% | 29.58% | |||
| EPS Diluted | -28.28% | -7.19% | |||
| Normalized Diluted EPS | -95.36% | 29.58% | |||
| Average Basic Shares Outstanding | 0.08% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||